Home › NCT07420803

A Study Of Auricular Transcutaneous Vagus Nerve Stimulation In Chronic Dizziness

Efficacy Of Auricular Transcutaneous Vagus Nerve Stimulation In Treating Chronic Dizziness

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Age 18-75, Persistent Postural-Perceptual Dizziness (PPPD) diagnosis per International Classification of Vestibular Disorders (ICVD).
* Persistent dizziness ≥3 months and at least 1 dizziness exacerbation/day during 2-week run-in.
* On stable medications/therapy for ≥4 weeks prior to baseline (if any).

Exclusion Criteria:

* Uncompensated peripheral/central vestibular deficit, sensory-afferent or cerebellar ataxia.
* Cardiac disease (coronary disease, unstable arrhythmia), recurrent syncope (\>1 in past 12 months).
* Neck surgery, vagotomy, or any condition interfering with vagal stimulation.
* Pregnancy.

About the study

The purpose of this study is to measure the change in dizziness, as measured by change in Dizziness Handicap Inventory (DHI) score, following a 4-week treatment period with auricular transcutaneous vagus nerve stimulation (aTVNS).

What is being tested

• Sham Device (other)
• Auricular transcutaneous vagus nerve stimulation (other)

Sponsor: Mayo Clinic · Participants: 60 · Started: Mar 23, 2026

Contact the study team

• Colton Clayton, Au.D., Ph.D. · Phone: 904-953-2945

Official record on ClinicalTrials.gov — NCT07420803

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.